Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Buy now fake rolex

Approvals Action
ViiV & BioMarin new drugs

Posted 19 July 2021 

Two new drugs - ViiV Heathcare's Rukobia and BioMarin's Palynziq - have been registered on the ARTG along with generics of already PBS-listed therapies.

Rukobia is the first of a new class called attached inhibitors designed to target the first step of the HIV lifecycle.

It is indicated in combination with other antiretroviral agents for the treatment of heavily treatment-experienced adults with multidrug-resistant HIV infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen due to resistance, intolerance or safety considerations.

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Top of the Hill
Pitfalls may plague NMP review
With an election in play, will it arrive too late?
Approvals Action
First copy of Halaven ticked
Along with other generics of already PBS-listed drugs